Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesContinued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease
Evidence-Based Medicine, 08/13/09
Hirsch C – In patients with Alzheimer disease, continued use of antipsychotic drugs increased long–term mortality.
Methods- Randomised placebo–controlled trial
- Patients: 165 patients (mean age 85 y, 76% women) who lived in nursing or residential homes, had possible or probable Alzheimer disease and a Mini–Mental State Examination score >6 or Severe Impairment Battery score >30, and were taking antipsychotic drugs (APDs) for >=3 months for behavioural or psychiatric disturbance (risperidone, >=0.5 mg/d or >=10 mg of chlorpromazine or equivalent of thioridazine, haloperidol, or trifluoperazine).
- Exclusion criteria were inability to take capsules or complete baseline assessment for primary outcomes, prolonged QT interval corrected for heart rate on electrocardiogram in patients using thioridazine, and any physical condition that would make participation distressing.
- 83 patients were allocated to continued use of their APDs for 12 months at prespecified very low, low, or high doses (risperidone or trifluoperazine, 0.5–2 mg/d, chlorpromazine, 12.5–50 mg/d haloperidol, 0.75–3 mg/d) that were closest to the dose taken at study entry; 82 were switched to placebo.
- Continuing APDs for 12 months increased mortality more than placebo at 24–54 months; groups did not differ at 12 months
Today in Geriatric Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
What is the association between depression and Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
The Occurence of Mood and Anxiety Disorders in Heart Transplant Recipients
Transplantation Proceedings, 11/02/09
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Sponsor
Article Search
Sponsor